vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Trip.com Group Ltd (TCOM). Click either name above to swap in a different company.
Trip.com Group Ltd is the larger business by last-quarter revenue ($304.6M vs $196.9M, roughly 1.5× Pacira BioSciences, Inc.).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Trip.com Group Limited is a multinational travel agency headquartered in Shanghai, China. It is the largest online travel service provider in the world.
PCRX vs TCOM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $304.6M |
| Net Profit | — | $84.6M |
| Gross Margin | 79.5% | 78.8% |
| Operating Margin | 1.2% | 16.5% |
| Net Margin | — | 27.8% |
| Revenue YoY | 5.1% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.05 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $304.6M | ||
| Q3 25 | $179.5M | — | ||
| Q2 25 | $181.1M | — | ||
| Q1 25 | $168.9M | — | ||
| Q4 24 | $187.3M | — | ||
| Q3 24 | $168.6M | — | ||
| Q2 24 | $178.0M | $242.7M | ||
| Q1 24 | $167.1M | — |
| Q4 25 | — | $84.6M | ||
| Q3 25 | $5.4M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $4.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | — | ||
| Q2 24 | $18.9M | $73.8M | ||
| Q1 24 | $9.0M | — |
| Q4 25 | 79.5% | 78.8% | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | 81.8% | ||
| Q1 24 | 71.6% | — |
| Q4 25 | 1.2% | 16.5% | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | — | ||
| Q2 24 | 15.9% | 27.8% | ||
| Q1 24 | 7.9% | — |
| Q4 25 | — | 27.8% | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | — | ||
| Q2 24 | 10.6% | 30.4% | ||
| Q1 24 | 5.4% | — |
| Q4 25 | $0.05 | $0.12 | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | $0.11 | ||
| Q1 24 | $0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $10.8B |
| Total DebtLower is stronger | $372.2M | $4.2B |
| Stockholders' EquityBook value | $693.1M | $23.8B |
| Total Assets | $1.3B | $36.9B |
| Debt / EquityLower = less leverage | 0.54× | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $10.8B | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | $12.4B | ||
| Q1 24 | $325.9M | — |
| Q4 25 | $372.2M | $4.2B | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $8.2B | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $23.8B | ||
| Q3 25 | $727.2M | — | ||
| Q2 25 | $757.8M | — | ||
| Q1 25 | $798.5M | — | ||
| Q4 24 | $778.3M | — | ||
| Q3 24 | $749.6M | — | ||
| Q2 24 | $879.3M | $18.1B | ||
| Q1 24 | $892.2M | — |
| Q4 25 | $1.3B | $36.9B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | $34.2B | ||
| Q1 24 | $1.6B | — |
| Q4 25 | 0.54× | 0.18× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | — |
| Free Cash FlowOCF − Capex | $43.5M | — |
| FCF MarginFCF / Revenue | 22.1% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | — | ||
| Q3 25 | $60.8M | — | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $35.5M | — | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $53.9M | — | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $49.1M | — |
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — | ||
| Q1 24 | $46.3M | — |
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — | ||
| Q1 24 | 27.7% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — | ||
| Q1 24 | 5.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
TCOM
| Others | $273.0M | 90% |
| Other | $31.6M | 10% |
